Company / Shareholders' Equity
Corvus Pharmaceuticals, Inc. Shareholders' Equity History
FY2015-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$32.6M
FY2024
5-year range
$32.6M / $97.2M
FY2020-FY2024
Trend
-15.8%
vs FY2023
Sector context
#188 of 215
Health Care
What the data says
Corvus Pharmaceuticals, Inc.'s shareholders' equity of $33M is lower than 87% of companies in the Health Care sector (FY2024). Shareholders' Equity has declined for 3 consecutive years, from $97M in FY2021 to $33M in FY2024.
Based on SEC 10-K filings.
$33M in FY2024 with a 5-year CAGR of -14.5%.
Declined from $56M to $33M over the past 2 years.
Health Care sector context is included.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- -30.5%
- 5-Year CAGR
- -14.5%
- 10-Year CAGR
- -
Sector benchmark
Bottom 13% in Health CareTop 87% of 215This company $32.6M Sector average $2.6B
▼
-98.7% below sector average
Key checks
Key Insights
- Corvus Pharmaceuticals, Inc.'s shareholders' equity has declined for 3 consecutive years.
- 5-year CAGR of -14.5%, indicating a declining trend.
- In FY2024, shareholders' equity decreased 15.8% year-over-year.
- Ranks #188 out of 215 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -0.67 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $32.6M | -15.8% |
| FY2023 | $38.7M | -31.1% |
| FY2022 | $56.1M | -42.2% |
| FY2021 | $97.2M | +34.7% |
| FY2020 | $72.1M | +1.5% |
| FY2019 | $71.1M | -35.6% |
| FY2018 | $110.3M | +30.1% |
| FY2017 | $84.8M | -36.1% |
| FY2016 | $132.8M | +527.0% |
| FY2015 | -$31.1M | -19460.4% |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026